Aurinia Pharmaceuticals (AUPH) Other Accumulated Expenses (2019 - 2026)

Aurinia Pharmaceuticals' Other Accumulated Expenses history runs 8 years deep, the most recent figure standing at $2.5 million for Q1 2026.

• Quarterly Other Accumulated Expenses rose 48.79% year-over-year to $2.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.5 million (up 48.79% YoY) and the FY2025 annual result came in at $2.5 million, up 61.99% from the prior year.
• Other Accumulated Expenses was $2.5 million for Q1 2026 at Aurinia Pharmaceuticals, up from $2.5 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $2.6 million in Q3 2023 and bottomed at $502000.0 in Q1 2022.
• A 5-year average of $1.8 million and a median of $2.0 million in 2023 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Other Accumulated Expenses plunged 88.79% — and 2023, when it soared 294.22%.
• Aurinia Pharmaceuticals' Other Accumulated Expenses stood at $2.0 million in 2022, then increased by 17.46% to $2.4 million in 2023, then sank by 35.89% to $1.5 million in 2024, then surged by 61.99% to $2.5 million in 2025, then climbed by 1.69% to $2.5 million in 2026.
• Business Quant data shows AUPH's Other Accumulated Expenses at $2.5 million in Q1 2026, $2.5 million in Q4 2025, and $2.5 million in Q3 2025.